Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.